Our website have detected that you are using an outdated browser that will prevent you from accessing certain features. klikk for mer informasjon.
Cart
Handlekurv

INVESTORRELASJONER

Her finner du informasjon på engelsk som gir deg oversikt over Zinzinos økonomiske resultat, samt strategisk retning fremover.


ZINZINO AB (PUBL): Zinzino announces launch of Taiwan as next step in the global expansion

The global, direct selling company within test-based, scientifically proven nutrition is very proud to announce the launch of its business in Taiwan on September 9, 2021 as a strategic part of the company’s mission towards global expansion. After several years of preparing the launch of the Taiwan market and having carried out multiple market establishment processes in recent years, Zinzino has learned the importance of ensuring thorough preparatory work and adapting to the local conditions in each market. Profitable growth is an important business strategy for the e-commerce-based Les mer »

Published: 9 sep Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT AUGUST 2021

Strong sales growth during August; Zinzino group revenue increased with a total of 14%, compared with the previous year. The revenue in August for Zinzino's sales markets increased by 13% to SEK 92.2 (81.9) million due to strong growth in several regions. Faun Pharma's external sales increased by 37% and amounted to SEK 4.8 (3.5) million. Overall, the Group increased revenues by 14% to SEK 97.0 (85.4) million compared with the previous year. Accumulated revenue for January – August 2021 increased by 23% to SEK 851.3 (690.9) million. Revenues were distributed as follows: Regions,MSEK Les mer »

Published: 3 sep Last ned PDF


ZINZINO AB (PUBL): INTERIM REPORT SECOND QUARTER 2021

INCREASED PROFIT FORECAST AFTER ANOTHER STRONG QUARTER The second quarter of 2021 was yet another quarter in which good sales growth was combined with high profitability. Total revenues in the Group increased by 18% and amounted to SEK 322.4 (274.3) million. EBITDA result amounted to SEK 33.4 (16.0) million for the quarter and the EBITDA margin amounted to 10.4% (5.8%). The margin improvement is achieved through economies of scale due to improved efficiency in IT systems, logistics and within the organization. During the quarter, sales started in India, and Malaysia achieved full market Les mer »

Published: 27 aug Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JULY 2021

Strong sales growth during July; Zinzino group revenue increased with a total of 11%, compared with the previous year. The revenue in July for Zinzino's sales markets increased by 13% to SEK 96.3 (85.3) million due to strong growth in several regions. Faun Pharma's external sales decreased by 23% and amounted to SEK 3.0 (3.9) million. Overall, the Group increased revenues by 11% to SEK 99.3 (89.2) million compared with the previous year. Accumulated revenue for January – July 2021 increased by 25% to SEK 755.2 (605.5) million. Revenues were distributed as follows: Regions,MSEK Les mer »

Published: 5 aug Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2021

Strong sales growth during Q2: Zinzino group revenue increased with a total of 17%, compared with the previous year. The revenue in June for Zinzino's sales markets increased by 8% to SEK 102.4 (94.6) million due to solid growth in several regions. Faun Pharma's external sales decreased by 28% and amounted to SEK 3.8 (5.3) million due to high internal production during the month. Overall, the Group increased revenues by 6% to SEK 106.2 (99.9) million compared with the previous year. The second quarter of 2021 became a strong quarter; the Zinzino based revenue in April - June increased 18% Les mer »

Published: 5 jul Last ned PDF


ANNUAL REPORT ENGLISH 2020 ZINZINO AB (PUBL)

Zinzino (publ.) announces that the Annual Report for 2020 is now available for download in English at the company’s website, www.zinzino.com.   For more information: Fredrik Nielsen, CFO Zinzino + 46 (0) 707 900 174, zinzino.com Pictures for publication free of charge: Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollblom@zinzino.com Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se Les mer »

Published: 7 jun Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT MAY 2021

Strong sales growth during May; Zinzino group revenue increased with a total of 26%, compared with the previous year. The revenue in May for Zinzino’s sales markets increased by 31% to SEK 104.3 (79.4) million due to strong growth in several regions. Faun Pharma's external sales decreased by 35% and amounted to SEK 4.5 (6.9) million. Overall, the Group increased revenues by 26% to SEK 108.8 (86.3) million compared with the previous year. Accumulated revenue for January – May 2021 increased by 32% to SEK 548.7 (416.5) million. Revenues were distributed as follows: Regions, MSEK Les mer »

Published: 3 jun Last ned PDF


ZINZINO AB (PUBL): Zinzino announces the launch of Malaysia as next step in their global expansion

Zinzino is very proud to announce the launch of its business in Malaysia on June 3, 2021 as a strategic part of the company’s global expansion strategy. After several years of preparing the launch of the Malaysian market and having carried out multiple country establishment processes in recent years, Zinzino has learned the importance of ensuring thorough preparatory work and adapting to the local conditions in each market. Profitable growth is an important business strategy for the e-commerce-based health tech company Zinzino. During 2020 the company sales target was exceeded Les mer »

Published: 3 jun Last ned PDF


ANNOUNCEMENT FROM THE ANNUAL GENERAL MEETING

Zinzino AB (publ.) held its Annual General Meeting today, May 20, where it was mainly decided: · to adopt the income statement and balance sheet, and the consolidated income statement and consolidated balance sheet, · to distribute a dividend of SEK 1.25 per share for the financial year 2020 and to bring the remaining part of the retained earnings forward, · to grant discharge from liability to the Board members and the CEO, · to elect Hans Jacobsson as Chairman of the Board and Staffan Hillberg, Pierre Mårtensson, Ingela Nordenhav and Anna Frick as Board members, · that a Les mer »

Published: 20 mai Last ned PDF


ZINZINO AB (PUBL): INTERIM REPORT FIRST QUARTER 2021

MAINTAINED STRONG SALES GROWTH WITH RECORD PROFITABILITY The first quarter of 2021 was yet another quarter in which good sales growth was combined with high profitability. Total revenues in the Group increased by 38% and amounted to SEK 333.4 (242.1) million, after sales growth in all regions except the Nordics. Strongest growth continued to be found among the other European regions. Asia and North America also increased significantly during the quarter. Profitability was also very good, and the EBITDA result amounted to SEK 37.3 (26.3) million for the quarter. The EBITDA margin thus Les mer »

Published: 18 mai Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT APRIL 2021

Strong sales growth during April; Zinzino group revenue increased with a total of 21%, compared with the previous year. The revenue in April for Zinzino's sales markets increased by 17% to SEK 98.7 (84.2) million due to strong growth in several regions. Faun Pharma's external sales increased by 97% and amounted to SEK 7.5 (3.8) million. Overall, the Group increased revenues by 21% to SEK 106.2 (88.0) million compared with the previous year. Accumulated revenue for January – April 2021 increased by 33% SEK 439.7 (330.2) million. Revenues were distributed as follows: Regions,MSEK Les mer »

Published: 4 mai Last ned PDF


ANNUAL REPORT ENGLISH 2020 ZINZINO AB (PUBL)

Zinzino (publ) announces that the Annual Report for 2020 is now published in Swedish at the company’s website, zinzino.com. An English version will be published within 45 days.  https://zinzinowebstorage.blob.core.windows.net/financialdocuments/Zinzino-arsredovisning-2020.pdf Zinzino will hold the Annual General Meeting on Thursday May 20th, 2021. Taking into account the health of both the shareholders and the company representatives as well as ongoing efforts to limit the spread of infection, the Annual General Meeting will be held without the possibility of physical participation. Les mer »

Published: 28 apr Last ned PDF


NOTICE OF THE ANNUAL GENERAL MEETING OF ZINZINO AB (publ.)

The shareholders of Zinzino AB (publ), org. no. 556733-1045 (the “Company”) are hereby invited to participate in the Annual General Meeting on Thursday, 20 May 2021. 2021 ANNUAL GENERAL MEETING FORMAT In light of the extraordinary situation society finds itself in due to coronavirus, the format of the 2021 Annual General Meeting of Zinzino AB will be adapted accordingly. Taking into account the health of both the shareholders and the company representatives as well as ongoing efforts to limit the spread of infection, the Annual General Meeting will be held without the possibility of Les mer »

Published: 21 apr Last ned PDF


ZINZINO AB (PUBL): A new signature BalanceOil from the pioneers of test-based nutrition

The global, Scandinavian health and wellness brand is taking the next step in its ambition to shape the future of nutrition with test-based, scientifically proven supplements. BalanceOil+ Premium with its unparalleled supply of polyphenols and phytonutrients is the D2C company’s latest addition to their range of BalanceOils restoring Omega levels and protecting the cells from oxidative stress. In this premium version, Zinzino’s exceptional and innovative blend of natural fish oil and vitamin D3 also includes a scientifically certified measure of R.E.V.O.O; the company’s private label of Les mer »

Published: 15 apr Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q1 2021

Strong sales growth during Q1; Zinzino group revenue increased with a total of 37%. The revenue in March for Zinzino's sales markets increased by 56% to SEK 120.6 (77.4) million due to strong growth in several regions. Faun Pharma's external sales increased by 86% and amounted to SEK 5.2 (2.8) million. Overall, the Group increased revenues by 57% to SEK 125.8 (80.2) million compared with the previous year. The Zinzino based revenue in January – March increased 38% MSEK 315.1 (228.7) million compared with previous year. Total group revenue increased 37% to SEK 332,4 (242,1) million. Les mer »

Published: 7 apr Last ned PDF


ZINZINO AB (PUBL): Zinzino announces the launch of India as next step in their global expansion strategy

Zinzino is very proud to announce the launch of India as the company’s next step in their global expansion strategy. After several years of preparing the launch of the Indian market and having carried out multiple country establishment processes in recent years, the company has learned the importance of ensuring thorough preparatory work and adapting to the local conditions in each market.Profitable growth is an important business strategy for the e-commerce-based health tech company Zinzino. During 2020 the company sales target was exceeded by an excellent sales growth and a strong EBITA Les mer »

Published: 6 apr Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2021

Strong sales growth during February; Zinzino group revenue increased with a total of 33%, compared with the previous year. The revenue in February for Zinzino's sales markets increased by 30% to SEK 94.4 (72.5) million due to strong growth in several regions. Faun Pharma's external sales increased by 81% and amounted to SEK 6.7 (3.7) million. Overall, the Group increased revenues by 33% to SEK 101.1 (76.2) million compared with the previous year. Accumulated revenue for January – February 2021 increased by 29% SEK 208.1 (161.9) million. Revenues were distributed as follows: Regions, Les mer »

Published: 3 mar Last ned PDF


ZINZINO AB (PUBL): YEAR-END REPORT 2020

INCREASED SHARE DIVIDEND AFTER RECORD CLOSING OF THE YEAR The fourth quarter of 2020 was the strongest quarter ever in the Company’s history regarding sales. Total revenues in the Group increased by 44% and amounted to SEK 340.4 (236.3) million. This is due to sales growth in all regions. The strongest growth continued to be found in the Central European countries, but Asia and North America also increased significantly during the quarter. Profitability was also very good and the EBITDA result amounted to SEK 37.4 (6.3) million for the quarter. The EBITDA margin amounted to the record Les mer »

Published: 26 feb Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JANUARY 2021

Solid sales growth during January; Zinzino group revenue increased with a total of 26%, compared with the previous year. The revenue in January for Zinzino's sales markets increased by 30% to SEK 102.3 (78.7) million due to strong growth in several regions. Faun Pharma's external sales decreased by 23% and amounted to SEK 5.3 (6.9) million. Overall, the Group increased revenues by 26% to SEK 107.6 (85.6) million compared with the previous year. Revenues distributed as follows: Regions,MSEK 21-jan 20-jan Change YTD 2021 YTD 2020 Change The Nordics 33.0 33.0 Les mer »

Published: 3 feb Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT 2020

Strong sales growth during 2020; Zinzino group revenue increased with a total of 44% in Q4 and 48% for the full year 2020, compared with the previous year. The revenue in December for Zinzino's sales markets increased by 77% to SEK 127.9 (72.3) million due to strong growth in many regions and countries. Faun Pharma's external sales increased by 158% and amounted to SEK 6.2 (2.4) million. Overall, the Group increased revenues by 80% to SEK 134.1 (74.7) million compared with the previous year. The fourth quarter of 2020 became the strongest quarter in the history of the company. The Zinzino Les mer »

Published: 7 jan Last ned PDF


ZINZINO AB (PUBL): Further expansions of the Zinzino global web shop

Zinzino is very proud to announce the launch of a global web shop for distributors in more than 60 countries who may now start operating under the Zinzino flag. This is an approach that reduces the pressure to open full-scale markets, which requires a lot of attention from the organisation. In tandem with the launch of the global web shop, the establishment processes continue in several markets including the Asian markets that have all become available through the acquisition of VMA Life. Having carried out multiple establishment processes in recent years, the company has learned the Les mer »

Published: 15 des Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2020

Solid sales growth during November; Zinzino group revenue increased with a total of 36%, compared with the previous year. The revenue in November for Zinzino's sales markets increased by 35% to SEK 93.7 (69.3) million primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 48% and amounted to SEK 4.3 (2.9) million. Overall, the Group increased revenues by 36% to SEK 98.0 (72.2) million compared with the previous year. During the last days of November Zinzino’s Black Friday campaign was carried out with a very successful outcome, and a Les mer »

Published: 3 des Last ned PDF


ZINZINO AB (PUBL): INTERIM REPORT THIRD QUARTER 2020

HISTORICAL ALL-TIME HIGH FOR ZINZINO – WE’RE INCREASING THE PROFIT FORECAST SIGNIFICANTLY The third quarter 2020 was the strongest quarter in the company’s history in terms of sales. Total revenues in the Group increased by 51% and amounted to SEK 281.8 (186.5) million. This is due to sales growth in all regions. The strongest growth continued to be in the Central European countries, but North America also increased significantly during the quarter. Profitability was also very good and the EBITDA result amounted to SEK 28.8 (4.4) million for the quarter. The EBITDA margin consequently Les mer »

Published: 20 nov Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT OCTOBER 2020

Solid sales growth during October; Zinzino group revenue increased with a total of 21%, compared with the previous year. The revenue in October for Zinzino's sales markets increased by 18% to SEK 100.8 (85.1) million primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 63% and amounted to SEK 7.0 (4.3) million. Overall, the Group increased revenues by 21% to SEK 107.8 (89.4) million compared with the previous year. Accumulated revenue for January – October 2020 increased by 45% SEK 906.1 (623.2) million. Revenues distributed as follows: Les mer »

Published: 3 nov Last ned PDF